10 completed, 3 recruiting, 2 active not recruiting, 2 terminated. 18 Phase 1, 10 Phase 2.
Follow alectinib: new trials by email Literature Review of alectinib trials Research Report on alectinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa) Alectinib - Bone Cancer | Phase 1 / Phase 2 | Not yet recruiting | China Medical University Hospital | 10 | 2026-05-15 | 2026-05-11 |
| A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL) Alectinib, Duvelisib - Anaplastic Lymphoma Kinase, Anaplastic Large Cell Lymphoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2025-08-08 | 2026-05-26 |
| Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements Alectinib, Stereotactic Radiosurgery - Lung Cancer, NSCLC | Phase 1 / Phase 2 | Recruiting | Joshua Palmer | 56 | 2024-03-07 | 2026-04-08 |
| Alectinib Pharmacokinetic in Patients With NSCLC Alectinib Oral Product - Non-small Cell Lung Cancer Stage IIIB, ALK Gene Mutation | Phase 1 / Phase 2 | Recruiting | Instituto Nacional de Cancerologia de Mexico | 45 | 2022-05-01 | 2026-04-08 |
| Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1 Alectinib (Alecensa), Nivolumab (Opdivo) - Hepatocellular Carcinoma | Phase 1 | Completed | China Medical University Hospital | 5 | 2022-02-16 | 2026-03-19 |
| A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors Alectinib - ALK Fusion-positive Solid or CNS Tumors | Phase 1 / Phase 2 | Active not recruiting | Hoffmann-La Roche | 42 | 2021-09-14 | 2026-11-12 |
| NCT Neuro Master Match - N²M² (NOA-20) APG101, Alectinib, Idasanutlin - Glioblastoma, Adult | Phase 1 / Phase 2 | Completed | University Hospital Heidelberg | 228 | 2018-05-07 | 2023-09-28 |
| A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC Alectinib, Cobimetinib - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Active not recruiting | Massachusetts General Hospital | 16 | 2017-09-14 | 2026-05-08 |
| A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer Alectinib - ALK-positive Non-small Cell Lung Cancer (NSCLC), RET-positive Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Terminated | Dana-Farber Cancer Institute | 5 | 2017-06-19 | 2021-09-27 |
| Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib Alectinib - Hepatic Impairment | Phase 1 | Completed | Hoffmann-La Roche | 28 | 2015-12-04 | 2018-08-24 |
| Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer Alectinib, Bevacizumab - Non-Small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Terminated | Massachusetts General Hospital | 11 | 2015-09-28 | 2025-05-13 |
| A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC) Alectinib, Atezolizumab, Erlotinib - Non-Small Cell Lung Cancer | Phase 1 | Completed | Hoffmann-La Roche | 52 | 2014-04-03 | 2020-04-21 |
| A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy Volunteers Alectinib, Posaconazole - Healthy Volunteer | Phase 1 | Completed | Hoffmann-La Roche | 23 | 2013-12-01 | 2016-10-11 |
| A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers. Alectinib, Esomeprazole, High Fat and Calorie Meal - Healthy Volunteer | Phase 1 | Completed | Hoffmann-La Roche | 42 | 2013-12-01 | 2016-10-07 |
| A Study of the Elimination, Pharmacokinetics, and Metabolism of RO5424802 RO5424802 - Healthy Volunteer | Phase 1 | Completed | Hoffmann-La Roche | 6 | 2013-11-01 | 2016-11-02 |
| A Study of the Effect of Multiple Doses of Rifampin on the Single Dose Pharmacokinetics of RO5424802 RO5424802, rifampin - Healthy Volunteer | Phase 1 | Completed | Hoffmann-La Roche | 24 | 2013-10-01 | 2016-12-21 |
| A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) Alectinib - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 134 | 2013-09-30 | 2018-08-21 |
| A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment Erlotinib, Alectinib - Non-Small-Cell Lung Carcinoma | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 138 | 2013-06-20 | 2018-11-02 |
Carcinoma, Non-Small-Cell Lung (7) · Brain Neoplasms (2) · Lung Neoplasms (2) · Bone Neoplasms (1) · Carcinoma, Hepatocellular (1) · Central Nervous System Neoplasms (1) · Glioblastoma (1) · Lymphoma, Large-Cell, Anaplastic (1) · Thyroid Neoplasms (1)
Hoffmann-La Roche (9) · China Medical University Hospital (2) · Massachusetts General Hospital (2) · Dana-Farber Cancer Institute (1) · Instituto Nacional de Cancerologia de Mexico (1) · Joshua Palmer (1) · Memorial Sloan Kettering Cancer Center (1) · University Hospital Heidelberg (1)
United States (12) · France (3) · South Korea (3) · Spain (3) · Taiwan (3) · United Kingdom (3) · Australia (2) · Canada (2) · Denmark (2) · Germany (2) · Italy (2) · Netherlands (2) · Belgium (1) · Brazil (1) · China (1)
Chang-Fang Chiu, Ph.D. (1) · Ibiayi T Dagogo-Jack, MD (1) · Joshua D Palmer, MD (1) · Justin Gainor, MD (1) · Mark Awad, MD (1) · Oscar G Arrieta Rodriguez, M.D., M.Sc. (1) · Robert Stuver, MD (1) · Wolfgang Wick, Prof. Dr. (1)
PMID 27863201, PMID 29748847, PMID 31706099, PMID 25153538, PMID 26708155, PMID 27130468, PMID 30052269, PMID 32009824, PMID 40913172, PMID 41213248
2015 (2)